News

MiMedx Empowers Healing with New EPIXPRESS® Allograft Solution

MiMedx Empowers Healing with New EPIXPRESS® Allograft Solution

Introduction to EPIXPRESS® Launch

MiMedx Group, Inc. (Nasdaq: MDXG) has revealed an exciting new development in the realm of wound care with the launch of EPIXPRESS®, a remarkable addition to their portfolio of Advanced Wound Care (AWC) solutions. This launch reflects the company’s ongoing commitment to innovate and provide effective healing treatments.

A Innovative Product Overview

EPIXPRESS® is designed to offer versatile applications in managing various wound types. According to Joseph H. Capper, the company’s Chief Executive Officer, EPIXPRESS is a product that builds on the popularity of EPIEFFECT® by enhancing it with fenestrations that allow better fluid movement through the tissue. This feature is vital for successful healing and directly addresses the needs expressed by healthcare professionals.

Characteristics of EPIXPRESS®

The innovative EPIXPRESS® expands MiMedx's range of PURION®-processed placental allografts aimed at assisting clinicians in treating both acute and chronic wounds that are difficult to heal. It is a lyophilized product featuring a robust tri-layer construction, which positions it as a standout treatment option.

The fenestrated structure incorporated in EPIXPRESS® provides significant benefits, particularly for various challenging conditions such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The design aims to facilitate fluid management, enhancing the healing process and supporting graft integration, even requiring securement with sutures.

Benefits of EPIXPRESS®

This advanced allograft serves a critical role in wound care by offering a biocompatible human Extracellular Matrix (ECM) enriched with over 300 regulatory proteins. These proteins contribute to a protective environment conducive to healing. EPIXPRESS® is intended to function as a barrier, providing essential protection to both acute and chronic wounds.

In addition to its other attributes, EPIXPRESS® is also included in the Medicare Part B Average Sales Price File, ensuring that healthcare providers and patients have access to this beneficial treatment solution. MiMedx remains committed to transparency and service, maintaining a focus on innovations that enhance the lives of patients.

MiMedx's Commitment to Healing

With a strong focus on improving healing outcomes, MiMedx has positioned itself as a leader in the field of wound care over the past decade. The company develops a broad spectrum of products designed for use in wound care, burn treatment, and surgical applications. Their vision to be the global leader in healing solutions guides their relentless pursuit of innovative therapies.

Conclusion: The Future of Wound Care

The introduction of EPIXPRESS® showcases MiMedx's dedication to pushing the boundaries of medical science in wound management. Their innovative approach and a commitment to market-driven solutions aim to empower healthcare professionals and enhance patient care.

For those looking to understand the implications of such advancements in medical technology, MiMedx provides easy access to their complete range of products and services through their website. The ongoing exploration of new solutions like EPIXPRESS® signals a positive trajectory in the treatment of challenging wounds.

Frequently Asked Questions

What is EPIXPRESS®?

EPIXPRESS® is a new lyophilized human placental-based allograft developed by MiMedx to assist in treating various chronic and acute wounds.

What are the key benefits of EPIXPRESS®?

This allograft features fenestrations for improved fluid movement and a biocompatible ECM that supports healing in challenging wound types.

How does MiMedx ensure product quality?

MiMedx utilizes rigorous quality control measures and adheres to regulatory standards, ensuring their products meet necessary healthcare requirements.

Where can I find more information about MiMedx's products?

More information about MiMedx’s portfolio, including EPIXPRESS®, can be found on their official website.

How can I contact MiMedx for inquiries?

For any inquiries, you can contact Matt Notarianni, Investor Relations at 470-304-7291 or via email at mnotarianni@mimedx.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring CRH Stock Performance Over Five Years and Beyond

Updated Category News Views 152

Understanding CRH's Impressive Growth CRH has displayed a remarkable performance in the stock market over the last five years, outshining many of its competitors with a 10.67% annualized return. This impressive growth translates to an average annual return of 23.49% for investors. Currently, CRH boasts a market capitalization of approximately $73.09 billion, making it a...

Continue Reading
Coordinated Care's Health Tour Expands Access Across WA

Updated Category News Views 78

A Grassroots Push for Health Equity Coordinated Care, a subsidiary of Centene Corporation, is hitting the road in Washington state. This isn't about just another healthcare campaign—you’ve got two vans, 'SeeMore' and 'Flossy', bringing essential vision and dental screenings right up to the folks who need them most. Taking Healthcare Directly to Communities Let's be...

Continue Reading
Italy's Antitrust Agency Investigates Snam-Edison Deal

Updated Category News Views 229

Investigation into the Snam and Edison Gas Storage Deal Italy's antitrust agency has recently initiated an investigation concerning the transaction between Snam and Edison involving Edison's gas storage unit. This move reflects the agency's commitment to maintaining healthy competition within the energy sector. Concerns Over Market Competition The Antitrust Authority,...

Continue Reading
Truist Financial Corporation's Quarterly Performance Insights

Updated Category News Views 240

Truist Financial's Results and Earnings Overview Truist Financial Corporation (TFC) announced its latest quarterly results, showcasing a robust financial performance that illustrates the company’s strategic focus on growth and stability. This release reflects the commitment of Truist to enhance the lives of its clients and communities by providing comprehensive...

Continue Reading
Investigation Into Possible Securities Fraud at UnitedHealth Group

Updated Category News Views 350

UnitedHealth Group Under Scrutiny for Securities Claims Ademi & Fruchter LLP has launched an investigation into potential securities fraud claims against UnitedHealth Group Incorporated (NYSE: UNH). This inquiry arises following inaccurate statements made by the company regarding its operational performance and future outlook. Investors and analysts alike express serious...

Continue Reading